Keratoconus patients more likely to develop sleep apnoea

Article

Keratoconus patients are more likely to develop sleep apnoea

Keratoconus patients are more likely to develop sleep apnoea, states a paper in the Journal of Cornea and External Disease.

Dr Michael Saidel, Section of Ophthalmology, University of Chicago, Illinois, USA, led a team that evaluated 92 keratoconus patients and 92 control patients. Each patient was classified as being high or low risk for sleep apnoea after answering the Berlin Questionnaire (BQ). The risk factors linked to high risk sleep apnoea was identified using logistic regression.

Out of the keratoconus patients questioned, 18 had a positive known sleep apnoea history and 49 were identified as high risk by the results of the BQ. Six of the 92 control patients had a positive known sleep apnoea history and 25 were identified as high risk.

In the control patients' age, body mass index and family history of sleep apnoea were the major risk factors for sleep apnoea. However, in keratoconus patients body mass index was the only risk factor for sleep apnoea.

The study results suggest that ophthalmologists should consider screening keratoconus patients for sleep apnoea.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.